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ARE ONLINE MANAGED PHYSICIAN PANELS A VIABLE SOURCE FOR 
SCIENTIFIC RESEARCH INITIATIVES?
Narayanan S
TNS Healthcare, New York, NY, USA
OBJECTIVES: Use of online “managed physician panels” for outcomes research 
purpose is not yet common. This study aims to compare practice characteristics, pre-
scribing patterns and attitudes between physicians in ‘TNS online managed panels’ 
and free-bound non-panel samples. METHODS: Physicians, especially Neurologists, 
were recruited from two sources in the United States for a Multiple Sclerosis (MS) 
research initiative: via online using TNS online managed panels (panelists), and via 
telephone (non-panelists). Practice characteristics (12-items), attitudes (76 items), 
treatment choices (8-items) and ratings of risk-factors (36-items) were measured in 
both cohorts using a standardized 45-minute-questionnaire; the results were analyzed 
to assess any statistical difference between the panelists and non-panelists across the 
measured domains. RESULTS: Survey results from Neurologists (167-panelists & 
97-non-panelists) were assessed. Overall, the concordance rate between the cohort 
responses was 95% (126-out-of-132-items). In 1 (out-of-12; 8.3%) practice charac-
teristic, namely, patient (pt) volume treated in a typical month, the cohorts differed 
(panelists-312pts/non-panelists-277pts). In 5 (out-of-76; 6.6%) attitudinal items (in 
7-point likert-scales), the individual item-response-scores marginally differed: impor-
tance of considering patient lifestyle while selecting MS therapy (panelists-4.8/ 
non-panelists-5.2), importance of brain lesions in measuring MS progression (panel-
ists-5.1/non-panelists-5.4), patients experience more side-effects with interferons than 
with glatiramer-acetate (panelists-5.8/non-panelists-5.3), interferon therapies with 
more frequent dosing are more effective (panelists-4.5/non-panelists-4.1), and physi-
cian opinion of what is best for patient supercedes patient’s personal preferences 
(panelists-4.2/non-panelists-3.8). There were no statistically signiﬁcant differences 
observed between the cohorts in treatment choices (all 8-items) and ratings of risk 
factors (all 36-items). CONCLUSIONS: The high concordance rates observed in the 
study cohort characteristics, attitudes and treatment practices strengthens the argu-
ment that online managed physician panels are viable options for scientiﬁc research 
studies, as they provide robust, cost-effective, quick sample of physicians, in addition 
to the well-known relatively high response rate.
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PATIENT REGISTRIES—A LITERATURE REVIEW OF RECENTLY 
REPORTED REGISTRY BASED STUDIES
Lis Y1, Bettinelli L2, Coward G1
1PAREXEL International, Uxbridge, Middlesex, UK, 2PAREXEL International, Berlin, Germany
Patient registries have been gaining increasing attention in recent years as health care 
providers, payers and regulators are requiring data that more accurately reﬂect clinical 
practice. However while the number of registry based studies is undoubtedly increas-
ing, little is known about the range and characteristics of registries supporting these 
studies. A review of the published literature was performed to identify recently 
reported studies based on patient registries. The search which covered the period 
January 2008 to April 2009 retrieved 278 evaluable articles reporting data from 
disease (55%), exposure (42%) and pregnancy (3%) registries. The majority of studies 
based on disease registries were focused on cardiovascular disease (49%), oncology 
(12%), renal disease (10%), haematology (8%) and gastrointestinal disease (7%). 
Data from exposure registries reported on patients who had received a pharmaceutical 
product (47%), device (28%), undergone a surgical procedure (22%) or other inter-
vention including radiotherapy (3%). Several registries have provided data able to 
support multiple publications for example the REACH registry. The most frequently 
performed assessments were evaluation of beneﬁt (46%), risk (34%), treatment prac-
tice (31%) and burden of disease (23%). Local or nationally representative patient 
registries accounted for 83% of the total reviewed. This might be expected given that 
data is most frequently required in the context of national health care systems by 
different stakeholders. However, one new insight this study provides is the use of 
studies based on an international registry (17%) where design, implementation and 
management provide much bigger challenges. Further analysis is underway. This 
research has conﬁrmed that patient registries are being used to provide evidence 
to inform health care decision making, improve disease management and advance 
knowledge on the beneﬁts, risks and cost effectiveness of different interventions in 
clinical practice.
DIABETES/ENDOCRINE DISORDERS – Clinical Outcomes Studies
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A COMPARISON OF CLINICAL EFFICACY OF INSULIN GLARGINE 
ADDED TO ORAL ANTIDIABETIC DRUGS VS PREMIXED INSULINS 
ALONE IN THE TREATEMENT OF TYPE-2 DIABETES MELLITUS
Rogoz A1, Kucia K1, Skowron M1, Rys P1, Siejka S1, Palka I1, Gierczynski J2, Plisko R1, 
Wladysiuk M1
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OBJECTIVES: This study compared efﬁcacy and safety of insulin glargine (IGlar) 
when added to oral antidiabetic agents (OADs) with premixed human insulins alone 
in type-2 diabetes. METHODS: Comparison was based on randomized controlled 
trials (RCT) identiﬁed by means of systematic review, carried out according to the 
Cochrane Collaboration guidelines and Agency for Technology Assessment in Poland. 
The most important medical databases (EMBASE, MEDLINE and CENTRAL) were 
searched in October 2008. Two reviewers independently selected trials, assessed their 
quality and extracted data. Meta-analysis of head-to-head trials was performed to 
compare IGlar added to OADs with premixed insulins. RESULTS: Three RCTs (637 
patients) directly comparing IGlar added to OADs with premixed human insulins were 
identiﬁed and included in the analysis. Greater reduction of glycated hemoglobin 
(HbA1C) was found in glargine-treated patients than in patients using premixed insulins 
(WMD  0.33% [0.50; 0.16]). Proportion of patients achieving HbA1C a7% was 
also higher in IGlar group although the difference was on the border of statistical 
signiﬁcance (RR  1.26 [1.00; 1.59]). Moreover statistically signiﬁcant differences in 
favor of glargine were demonstrated in fasting plasma glucose level (WMD  0.87 
[1.21; 0.53]). More subjects treated with glargine achieved target FPG level (RB  
2.11 [1.41; 3.17], NNT  6.00 [3.97; 12.32]). No statistically signiﬁcant differences 
were found in the percentage of patients experiencing hypoglycemic episodes(RR  
0.90 [0.78; 1.04]). Weight gain was observed in both groups with no statistically sig-
niﬁcant differences (MD  0.70 kg [1.48; 0.08]). CONCLUSIONS: IGlar combined 
with OAD is associated with better glycemic control than premixed human insulins 
alone. Risks of hypoglycemia and weight gain are comparable in both arms. Acknowl-
edgements: This analysis was supported by Sanoﬁ-Aventis.     
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REAL WORLD CLINICAL EFFECTIVENESS OF SITAGLIPTIN THERAPY 
FOR MANAGEMENT OF TYPE 2 DIABETES: A RETROSPECTIVE 
DATABASE ANALYSIS
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OBJECTIVES: Sitagliptin is a dipeptidyl peptidase-4 inhibitor used to treat adults with 
type-2 diabetes (T2D). This study examined patient characteristics and clinical effec-
tiveness of sitagliptin in a managed care setting. METHODS: An administrative claims 
analysis was performed using data from the HealthCore Integrated Research database. 
Adults with a diagnosis of T2D, a new claim for sitagliptin (index medication) between 
October 1, 2006 and March 31, 2007, and q12 months pre- and post-index continu-
ous eligibility were included (n  3719). A subgroup analysis was performed for 
patients who had baseline (183 days pre-index—30 days post-index) and post-index 
(60–365 days) HbA1C (A1C) data to examine change in A1C after sitagliptin initia-
tion. RESULTS: Mean (SD) age of patients initiating sitagliptin was 56.0 (o10.0) years 
and 61% were male. Common co-morbidities were hypertension (84%), dyslipidemia 
(83%), and other cardiovascular diseases (25%). At baseline the patients were receiv-
ing an average (SD) of 1.9 (o1.0) antidiabetic medications. Commonly used antidia-
betic medications were metformin (58%), thiazolidinediones (41%), sulfonylureas 
(37%) and insulin (16%). While not an approved indication, there was a signiﬁcant 
increase in the use of insulin therapy from 16% to 25% in the post index period 
(p  0.0001). Fixed dose oral combination therapy also increased from 19% to 25% 
in the post-index period (p  0.0001). Mean (SD) baseline A1C in the subgroup (n  
726) was 8.02% (o1.56) with an absolute reduction of 0.54% (o1.44), (p  0.0001). 
Of 522 patients with a baseline A1C q 7.0%, 178 (34.1%) achieved an A1C of 
7.0%. CONCLUSIONS: Most of the patients initiating sitagliptin therapy were also 
using other antidiabetic medications at baseline. There was a signiﬁcant increase in 
concomitant use of ﬁxed dose combination and insulin therapy in 12 months following 
sitagliptin initiation. The mean reduction in A1C and the proportion of patients 
attaining A1C 7.0% were comparable to those observed in clinical trials.
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FORECASTING THE NUMBER OF DIABETIC PATIENS IN THE UNITED 
STATES IN 2050
Baser O1, Wang L2, Gust C2
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OBJECTIVES: Accounting for changing demography and diabetes prevalence rates, 
to project the number of people with diagnosed diabetes in US through 2050. 
METHODS: Our model proceeds in three steps using inverse probability weighting 
and raking.Created initial sampling weights, deﬁned as the inverse of the probability 
of selection, plays a pivotal role in desing-based inference in yielding estimates that 
are designed unbiased and consistent. Last, by applying procedure, known as raking, 
we adjust our initial weights so that marginal total of adjusted weight on speciﬁed 
characteristics agrees with the corresponding totals for the population. RESULTS: The 
total number of people with diabetes will rise to almost 26 million in 2025. This is 
projected at 200% increase over the 2000 levels. Note that these projections imply 
steady increase in the overall prevalence of diabetes. The largest increases in the 
number of people with diabetes likely to occur in the older age. The number of women 
75 years or greater of age with diabetes will increase almost 380% from 2000 levels. 
It is demographic changes that account for the largest share of the increase. Twenty 
percent of the overall projected growth will be due to population growth, 35% will 
be due to increase in prevalence rate and 45% will be due to changes in demographic 
compositions. CONCLUSIONS: Diabetes is already recognized as publich health 
problem of pandemic proportions. Our projection of diabetes burden in US indicate 
that the situtation may be more alarming than previously recognized. Advances in 
primary prevention may help reduce the number of people with diabetes. The eco-
nomic burden of diabetes is already staggering, and future increase in the number of 
people with the disease will increase the burden. Worldwide surveillance of diabetes 
is a necessary ﬁrst step toward its prevention and control.
